Disclosure: supply links may earn PepPal a commission at no cost to you
The slowing of gastric emptying caused by GLP-1 agonists could theoretically alter alcohol absorption patterns, though this mechanism remains speculative in the context of AUD
A landmark clinical trial reveals that a widely used obesity drug may also curb alcohol cravings and consumption, opening a potential new front in addiction treatment
This issue can arise when patients consume too few calories to maintain adequate protein intake, leading to muscle loss
Implications for telehealth and pharma marketers: The FDA is targeting marketing claims rather than pulling products, making positioningespecially comparisons to branded GLP-1sthe main risk area
3J), and mRNA quantification results of some genes were highly consistent with the RNA-seq data, thus validating the reliability of the transcriptome data (Fig